Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma
A phase 2 trial of tislelizumab, gemcitabine, cisplatin and S-1 in gallbladder cancer and other biliary tract cancers, run by National Cheng-Kung University Hospital, not yet recruiting.
Overview
Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma is a phase 2 interventional study registered as NCT06903273 by National Cheng-Kung University Hospital, with a registry enrolment figure of 35 participants, started 2025-07-01 and due to reach its primary completion in 2028-07-01. Interventions recorded: Tislelizumab. Conditions listed: Cholangiocarcinoma, Biliary Tract Cancer (BTC). Sites: Taiwan. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialChemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialPerioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialQL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialAdebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialAlternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialThe Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Gemcitabine and the tag gallbladder-deep-dive.
- TrialCTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
- TrialEnvafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.